Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.

Kim HK, Smiddy M, Hoffman RS, Nelson LS.

Pediatrics. 2012 Dec;130(6):e1700-3. doi: 10.1542/peds.2012-1342. Epub 2012 Nov 5.

PMID:
23129079
2.

Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone.

Pedapati EV, Bateman ST.

Pediatr Crit Care Med. 2011 Mar;12(2):e102-7. doi: 10.1097/PCC.0b013e3181f3a118.

PMID:
20921918
3.

Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.

Häkkinen M, Heikman P, Ojanperä I.

Forensic Sci Int. 2013 Oct 10;232(1-3):11-5. doi: 10.1016/j.forsciint.2013.06.017. Epub 2013 Jul 19.

PMID:
24053859
4.

Suboxone (buprenorphine/naloxone) toxicity in pediatric patients: a case report.

Schwarz KA, Cantrell FL, Vohra RB, Clark RF.

Pediatr Emerg Care. 2007 Sep;23(9):651-2.

PMID:
17876257
5.

Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.

Sekar V, Tomaka F, Lefebvre E, De Pauw M, Vangeneugden T, van den Brink W, Hoetelmans R.

J Clin Pharmacol. 2011 Feb;51(2):271-8. doi: 10.1177/0091270010365558. Epub 2010 Apr 26. No abstract available.

PMID:
20421512
6.

Adverse effects in children after unintentional buprenorphine exposure.

Geib AJ, Babu K, Ewald MB, Boyer EW.

Pediatrics. 2006 Oct;118(4):1746-51.

PMID:
17015570
7.

Pharmacokinetics of the combination tablet of buprenorphine and naloxone.

Chiang CN, Hawks RL.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S39-47. Review.

PMID:
12738349
8.

Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.

Yassen A, Olofsen E, van Dorp E, Sarton E, Teppema L, Danhof M, Dahan A.

Clin Pharmacokinet. 2007;46(11):965-80.

PMID:
17922561
9.

Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.

Douglas Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH.

Am J Drug Alcohol Abuse. 2013 Mar;39(2):80-5. doi: 10.3109/00952990.2013.764885.

PMID:
23421567
10.

Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.

Ciraulo DA, Hitzemann RJ, Somoza E, Knapp CM, Rotrosen J, Sarid-Segal O, Ciraulo AM, Greenblatt DJ, Chiang CN.

J Clin Pharmacol. 2006 Feb;46(2):179-92.

PMID:
16432270
11.

Buprenorphine and buprenorphine/naloxone intoxication in children - how strong is the risk?

Soyka M.

Curr Drug Abuse Rev. 2013 Mar;6(1):63-70. Review.

PMID:
23489089
12.

Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.

Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP.

Psychopharmacology (Berl). 1999 Jan;141(1):37-46.

PMID:
9952063
13.

Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.

Gruber VA, Rainey PM, Moody DE, Morse GD, Ma Q, Prathikanti S, Pade PA, Alvanzo AA, McCance-Katz EF.

Clin Infect Dis. 2012 Feb 1;54(3):414-23. doi: 10.1093/cid/cir799. Epub 2011 Nov 18.

14.

In-vitro and in-vivo characterization of a buprenorphine delivery system.

Kleppner SR, Patel R, McDonough J, Costantini LC.

J Pharm Pharmacol. 2006 Mar;58(3):295-302.

PMID:
16536895
15.

Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment.

Mégarbane B, Buisine A, Jacobs F, Résière D, Chevillard L, Vicaut E, Baud FJ.

J Subst Abuse Treat. 2010 Jun;38(4):403-7. doi: 10.1016/j.jsat.2010.01.006. Epub 2010 Feb 26.

PMID:
20189341
16.

Buprenorphine ingestion in a 23-month-old boy.

Swartzentruber GS, Richardson WH, Mack EH.

Hosp Pediatr. 2015 Mar;5(3):164-6. doi: 10.1542/hpeds.2014-0070. No abstract available.

17.

Transfer from high dose methadone to buprenorphine/naloxone.

Wallace M.

Aust Nurs J. 2011 Jul;19(1):42-3. No abstract available.

PMID:
21853690
18.

Exploratory buprenorphine ingestion in an infant.

Cho CS, Calello DP, Osterhoudt KC.

Ann Emerg Med. 2006 Jul;48(1):109. No abstract available.

PMID:
16781931
19.

Opioid-induced respiratory effects: new data on buprenorphine.

Dahan A.

Palliat Med. 2006;20 Suppl 1:s3-8.

PMID:
16764215
20.

Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.

Kögel B, Christoph T, Strassburger W, Friderichs E.

Eur J Pain. 2005 Oct;9(5):599-611.

PMID:
16139189

Supplemental Content

Support Center